A bit exciting than previous quarters as highlighted below:...

A bit exciting than previous quarters as highlighted below:

Research and development continue this quarter with further development of data analysis tools. Continued investment in real world data-gathering tools to increase the sophistication of analysis of user behaviour and pelvic health information is the cornerstone of company strategy. Analytica is currently updating its quality system and bringing a new contract manufacturer online, with the aim of re-registering with the FDA and resume exporting product to the US this quarter. Analytica is working closely with Navigant Capital Advisors LLC, (appointment, announced 6th November) with the process for the sale of the PeriCoach, AutoStart and AutoFlush.
As outlined in the Chairman’s address to the Annual General Meeting in November 2017, Analytica is achieving its goals set out at the Annual General meeting 2016 of being deal-ready. This quarter demonstrates further strong progress to the Company strategy; build a product that is best in class, gather evidence that the product performance is exceptional, and actively pursue partnering opportunities.